Quick Take
A 59-year-old man from New Zealand named Josh became the world's first international patient to complete satri-cel — the first CAR-T therapy ever approved for a solid tumor — at Jiahui International Cancer Center in Shanghai, and was discharged on August 16, 2026. The therapy targets CLDN18.2, a protein found on many gastric and gastroesophageal cancer cells, and is approved in China for patients whose disease has progressed after at least two prior lines of treatment. Josh was diagnosed with advanced gastroduodenal adenocarcinoma in late 2025, progressed through chemotherapy and immunotherapy at home, and travelled roughly 9,000 km to Shanghai for a treatment that existed nowhere else. His case is a milestone for two reasons at once: it is the first real-world use of a solid-tumor CAR-T in an international patient, and it signals that China's newest oncology therapies are now being actively sought by patients from other countries.
1. The Milestone: A "World First" with a Real Patient Behind It
CAR-T cell therapy has been one of the great success stories in blood cancers — leukemia, lymphoma, and multiple myeloma. Solid tumors, including stomach cancer, resisted the approach for years because their cells are harder for engineered immune cells to lock onto and penetrate.
Satri-cel changed that. It is the first CAR-T product approved anywhere for a solid tumor, cleared by China's NMPA in June 2026 for advanced gastric and gastroesophageal junction adenocarcinoma. Until this case, though, the therapy had been used only in Chinese patients through clinical trials and early commercial access.
On August 16, 2026, Jiahui International Cancer Center announced that Josh — the first non-Chinese patient to receive the therapy — had been discharged after more than a month of treatment. The center framed the event as "a historic milestone in making China's latest oncology innovations accessible to patients worldwide." That is not marketing language so much as a plain description of what happened: a patient crossed an ocean for a therapy that is, for now, available in only one country.
2. Josh's Journey: A Timeline
Josh's case is useful because it shows the entire international treatment path, not just the medical outcome.
The five steps that mattered:
- Late 2025 — diagnosis. Josh was diagnosed with advanced gastroduodenal adenocarcinoma and began standard treatment in New Zealand.
- Progression. Chemotherapy combined with immunotherapy failed to halt the disease. With conventional options narrowing, he began looking internationally.
- Biomarker testing. Guided by Jiahui, he was tested in New Zealand first — the result, CLDN18.2-positive and HER2-negative, matched satri-cel's indication. This step matters because it confirmed eligibility before he boarded a plane.
- July 6 — T-cell collection. After PET-CT imaging and multidisciplinary planning at Jiahui, Josh underwent leukapheresis (T-cell collection). His cells then entered a roughly three-week manufacturing process.
- August 16 — discharge. After the infusion and in-hospital monitoring, Josh was discharged and returned to New Zealand, with a handover call between his Shanghai doctor and his home oncologist.
3. What the Treatment Did — and the Honest Limits
The hospital's discharge report describes a patient who arrived in difficult shape. Josh had significant malignant ascites (fluid in the abdomen) and severe difficulty eating. Before the infusion, his ascites was being drained at up to 2,000 mL per day at its peak. By day 10 after the infusion, the malignant ascites had visibly receded, and his abdominal drain was removed before discharge. A traditional Chinese medicine team was brought in alongside oncology to help manage nausea and other side effects.
This is a single patient, not a clinical trial, and one case is not evidence of a cure. What it does show is that a patient with advanced, treatment-resistant gastric cancer could travel to China, receive a therapy that was not available at home, tolerate the process, and go home with meaningful symptom improvement.
For the broader picture, the underlying data is in the CT041-ST-01 trial published in The Lancet. Satri-cel cut the risk of disease progression or death by about 63% versus standard treatment (HR 0.37), with an objective response rate of 22% vs 4%. Median overall survival was 7.92 vs 5.49 months. Those are group-level numbers — real, but modest — and the full data and eligibility details are covered in our deep-dive on satri-cel.
Why this case still matters: the Lancet trial established that the therapy can work in principle. Josh's case shows the practical path — that a patient from outside China can actually get through the process, from overseas testing to discharge.
4. Why He Chose China — and Jiahui
Josh said he also received treatment plans from hospitals in Saudi Arabia and the United States. His reasons for choosing Shanghai are instructive for other patients weighing the same decision:
- The therapy itself. Satri-cel is approved only in China. For his specific disease — CLDN18.2-positive gastric cancer after multiple prior lines — it was, in his words, "the most accessible option."
- Responsiveness and communication. He cited the team's fast replies and smooth communication as a deciding factor.
- A familiar doctor. His lead physician, Dr. Linli Xuan, Chief of Medical Oncology at Jiahui, practiced in the United States for twenty years. Josh said that made communication, clinical flow, and cultural understanding feel familiar — a real consideration for a patient who had never been to China.
- Language and cultural adaptation. Jiahui's International Patient Office coordinates multilingual support, dietary and cultural preferences, and logistics — reducing the friction that many international patients worry about most.
Jiahui had already treated CAR-T patients from Singapore, the United States, New Zealand, Russia, and Pakistan — but only for blood cancers. Josh was its first solid-tumor international case, extending the center's CAR-T program from hematology into solid tumors.
5. How International Patients Actually Apply
The path Josh followed is reproducible, and the ordering matters. Do the testing first, before you travel.
- Records review. Send pathology reports, treatment history, recent imaging, and lab results to an international patient office or a hospital-matching service.
- Biomarker testing. Confirm CLDN18.2 status (and HER2) on tumor tissue — in Josh's case this was done at home before he flew. If untested, the hospital can retest from pathology slides.
- Eligibility confirmation. A multidisciplinary team confirms you meet the criteria: advanced gastric/GEJ adenocarcinoma, CLDN18.2-positive, at least two prior lines, and adequate organ function and performance status.
- Travel and treatment. Plan for roughly 4-8 weeks in China, covering collection, the 2-3 week manufacturing window, infusion, and monitoring.
- Handover home. Before discharge, your Shanghai team should coordinate with your home oncologist — as Jiahui did with Josh's New Zealand doctor — so follow-up care is continuous.
One caution: the manufacturing wait is the vulnerable part of the process. Patients whose disease is moving fast may not have the physical reserve to reach infusion. That is why starting the evaluation early — while the patient still has condition to spare — genuinely matters.
6. Frequently Asked Questions
Who was the first international patient to receive solid-tumor CAR-T in China?
Josh, a 59-year-old man from New Zealand, treated for advanced gastroduodenal cancer at Jiahui International Cancer Center in Shanghai. T-cell collection on July 6, 2026; discharged August 16, 2026.
What is satri-cel, and who is it for?
The world's first approved solid-tumor CAR-T, targeting CLDN18.2 in gastric and gastroesophageal junction cancer. Approved in China for advanced disease after at least two prior lines of therapy.
Why travel to China for it?
Because it is approved only in China. Patients with CLDN18.2-positive gastric cancer who have exhausted standard options have no equivalent approved therapy elsewhere.
Is one patient's improvement proof it works?
No. Josh's case is encouraging but is a single patient. The efficacy evidence is the randomized CT041-ST-01 trial, with its 63% reduction in progression or death risk and 22% response rate.
How long does treatment take in China?
About 4-8 weeks: records review, testing, a 2-3 week manufacturing window, infusion, and in-hospital monitoring. Josh's course ran just over one month.
How do I start?
Send your records for a free review — pathology, CLDN18.2 status, treatment history, imaging, and labs — and the hospital's team will confirm whether you are a candidate before any commitment.
Get a Free Hospital Recommendation & Cost Estimate
Tell us your diagnosis, CLDN18.2 status, and treatment history. We'll check your eligibility for solid-tumor CAR-T, match you with oncology centers running CLDN18.2 CAR-T programs, and get written treatment and cost assessments. No obligation, 100% confidential, we reply within 24 hours.
- 📧 Email: contact@chinahospitalsguide.com
- 💬 WhatsApp: +86 157 6310 7083
- 📨 Telegram: @chinahospitalguide
- 💬 WeChat: chinahospitalguide
- 🌐 Start Free Case Review
Medical Disclaimer This article is general educational content only and does not constitute medical advice, a treatment recommendation, or an invitation to seek care. It cannot replace an in-person consultation with a licensed physician. It reports on a single, publicly documented patient case and publicly published clinical data; neither is a promise of outcomes for any individual. Cell therapy has strict indications, contraindications, and safety risks. Whether CAR-T is suitable must be assessed by an oncology cell-therapy team at a qualified hospital. If you are ill, please follow the guidance of licensed clinicians at a proper medical institution.
Source disclosure This article is based on the official announcement from Jiahui International Cancer Center (July 7, 2026) and a discharge report published by Guangming Online / Consumer Daily (August 19, 2026), which were prepared with the patient's participation and consent. China Hospitals Guide is an independent hospital-matching platform and does not accept commissions from hospitals or guarantee referrals to any single institution.
Related Reading
- World's First CAR-T for Gastric Cancer: Satri-cel (CLDN18.2) in China — Trial Data, Eligibility & Risks
- CAR-T Therapy Hospitals in China 2026
- CAR-T Therapy Cost in China 2026
- Cancer Treatment in China
- For Singapore patients: Guide to Treatment in China
- For Indonesian patients: Panduan Berobat di Tiongkok